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Abstract
Background: Breakthrough cancer pain (BTcP) is defined according to its principal characteristics: high intensity,
short time interval between onset and peak intensity, short duration, potential recurrence over 24 h and
non-responsiveness to standard analgesic regimes. The Edmonton Classification System for Cancer Pain (ECS-CP)
is a classification tool that evaluates different dimensions of pain.
The aim of this study was to measure prevalence and the main characteristics of BTcP in a sample of advanced cancer
patients and to explore the complexity observed when ECS-CP is incorporated into BTcP diagnostics algorithm.
Methods: Descriptive prevalence study (Retrospective chart review). Davies’ algorithm was used to identify BTcP and
ECS-CP was used to recognize appropriate dimensions of pain. The study was conducted in a sample of advanced
cancer patients attending hospital outpatient clinic in Lleida, Spain. 277 patients were included from 01/01/2014 to
31/12/2015. No direct contact was made with participants. The following information was extracted from the palliative
care outpatient clinic database: age, gender, civil status, cognitive impairment status, functional performance status and
variables related to tumour. Only BTcP cases were included.
Results: Prevalence of BTcP was 39.34% (63.9% men). Mean of age was 68.2 years. Main diagnosis was lung cancer
(n = 154; 31.6%). Metastases were diagnosed in 83% of the sample. 138 patients (49.8%) were diagnosed with 1 type
of BTcP and 139 (50.2%) were diagnosed with more than one type of BTcP. In total, 488 different types of BTcP were
recorded (mean 1.75 ± 0, 9), 244 of these types (50%) presented a component of neuropathic pain. Addictive
behaviour, measured through CAGE test, was present in 29.2% (N = 81) of the patients and psychological distress
was present in 40.8% (n = 113).
Conclusions: Prevalence of BTcP (39.34%) is similar to the one reflected in the existing literature. Study results
indicate that the routine use of ECS-CP in a clinical setting allows us to detect more than one type of BTcP as
well as additional complexity associated with pain (neuropathic, addictive behavior and psychological distress).
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Background
In 1989, Portenoy and Hagen [1] defined breakthrough
cancer pain (BTcP) as the transient exacerbation of pain
occurring in a patient with otherwise stable pain in re-
ceipt of chronic opioid therapy. This pain is one of the
most difficult pain syndromes to treat. The term en-
compasses a diverse group of transient pains that vary
in their relationship to the fixed analgesic dose, tem-
poral characteristics, precipitating events, predictability,
pathophysiology, and aetiology [1, 2].
Later, BTcP was redefined as a transient exacerbation
of pain that occurs either spontaneously, or in relation
to a specific predictable or unpredictable trigger, despite
relatively stable and adequately controlled background
pain [3]. More recently, other authors [4–7] have im-
proved BTcP definition by adding severity of intensity
and the length between 30 and 60 min.
Prevalence of BTcP varies between 19 and 95% [8–11].
This is explained by the different definitions found in
the literature and also depending on the area where the
data are collected (inpatient or outpatient patients).
The prevalence of BTcP assessed in outpatient clinics
is 39.9% and in those assessed in palliative care units, is
80.5% [12].
It is therefore difficult to diagnose BTcP. For this rea-
son, many Scientific Societies related to cancer, palliative
care and pain, work to clarify the definition and the
accurate diagnosis of BTcP [13–17].
In the same way, different instruments have been de-
fined to facilitate the diagnostic approach of BTcP. We
highlight the Alberta Breakthrough Pain Assessment
Tool for Cancer Patients [18], the breakthrough pain as-
sessment tool (BAT) in cancer patients [19] and the Italian
Questionnaire for Breakthrough Pain (IQ-BTP) [20].
To improve the sensitivity of the diagnosis of BTcP,
several authors developed the so-called “Davies algo-
rithm” [21], recently validated by Weber K et al. [22].
Although the use of this algorithm is widespread, it is
not designed to replace clinical assessment.
Literature refers to BTcP as a single clinical entity with
several possible episodes in a single patient and the fact
that more than one different types of BTcP with several
episodes each in the same patient has not yet been
explored [16, 23, 24].
The pharmacological treatment of BTcP is based on
the use of the three-step ladder of the WHO [25, 26].
Considering the characteristics of BTcP in terms of
temporality and intensity, only Rapid Onset Opioids
(ROOs), mainly fentanyl, have been shown to be effect-
ive [27–29]. Zeppetella and Davies [30] conclude that
both oral and intranasal-Trans-mucosal fentanyl are ef-
fective for the treatment of BTcP episodes.
Early pharmacological approach is the cornerstone of
the treatment of BTcP [31]. Its improvement will also
enhance both the quality of life and the functionalism of
the patient [32].
The first choice of treatment is always oral and in
many cases, for the treatment of BTcP, the choice is
fast bioavailability treatments such as fentanyl. The
rapid bioavailability of fentanyl-based ROOs may lead
to episodes of abuse of these drugs; therefore it is ad-
visable to minimize the risk with a detailed appropri-
ately assessment [33, 34].
The Edmonton Classification System for Cancer Pain
(ECS-CP) derives from the Revised Edmonton Staging
System (rESS) from which construct, inter-rater reliability,
and predictive validity evidence have contributed to the
development of the ECS-CP. The five features of cancer
pain included -Pain Mechanism (N), Incident Pain (I),
Psychological Distress (P), Addictive Behavior (A) and
Cognitive Function (C)- have demonstrated value in pre-
dicting pain management complexity [35, 36].
The ECS-CP is a clinically relevant systematic frame-
work, which is able to detect differences in salient
pain classification features across diverse settings and
countries [37].
It is known that BTcP is difficult to diagnose and to
treat. We hypothesized that if we add the ECS-CP dur-
ing the diagnosis process, we find an added complexity
together with the incident features of the cancer pain.
This is because we can find other characteristics of pain
such as the neuropathic component, addiction and psy-
chological discomfort.
Therefore, the objectives of this retrospective review
were:
1. To describe the characteristics of the population
studied and the prevalence of BTcP in a sample of
advanced cancer patients treated at an outpatient
clinic.
2. To determine the number of different types of
BTcP diagnosed in each patient, regardless the
number of episodes of BTcP.
3. To explore the different pain features associated to
the diagnosis of BTcP
Methods
This was a retrospective and anonymous database re-
view of the patients attending for the first time at
Palliative Care outpatient clinic, which is maintained
at the Lleida University Hospital in Catalonia (Spain).
This study was approved by the Ethics Committee of
the Hospital Universitari Arnau de Vilanova in Lleida.
All data-analysis was performed anonymously without
an additional informed consent, according to its recom-
mendations. The administrative permissions required
were obtained in order to review patient records and use
the data.
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This Palliative Care outpatient clinic attends advanced
cancer patients early in the disease course as well as pa-
tients that are not receiving active treatment. The patients
were referred to the clinic by their reference oncologist
and the palliative care consultation team was the respon-
sible organ of the pain management.
Inclusion criteria: age > 18 years, diagnosis of advanced
cancer (non haematological) assisted at the outpatient
clinic of the Palliative care outpatient clinic suffering,
from BTcP due to cancer and without any cognitive im-
pairment (Pfeiffer test ≥ 4 errors). End-of-dose pain was
specifically excluded.
We defined BTcP according to Boceta et al. [38] as a
transitory exacerbation of pain lasting less than 60 min,
which occurs spontaneously or in association with a spe-
cific predictable or unpredictable trigger at some point
during the day in cancer patients, despite relatively and
adequately controlled background pain. BTcP was con-
sidered as those that have different characteristics in
terms of localization, intensity, mechanisms that trigger
it or intrinsic characteristics of pain (neuropathic vs.
nociceptive). The same type of BTcP can present with
several episodes (maximum 4 episodes per day). The lit-
erature review shows that there is not a broad consensus
about definition of BTcP therefore, to facilitate the
methodology of data collection; we included equal terms
BTcP and incidental pain.
A physician, also responsible for assessing pain and
other symptoms, evaluated all the patients attended in
the outpatient clinic. Pain was assessed using a Visual
Analogic Scale (VAS) and the cut-off value (VAS scale)
of patients for their background pain was VAS ≤ 3 during
the previous 7 days. All patients who reported ad-
equately controlled background pain (VAS ≤ 3) in the
previous week were further evaluated exhaustively. The
procedure to diagnose BTcP was done following the al-
gorithm of Davies [21] and according to the consensus
recommendations from the Spanish Pain Society. The al-
gorithm indicates that baseline pain must be adequately
controlled before a diagnosis of BTcP can be considered.
Each BTcP were located anatomically in the painful area
and each patient could present different types of pain. For
each type of BTcP, the ECS-CP test was later applied to as-
sess additional complexity. The ECS-CP classifies the dif-
ferent pain features according to its origin. This way, the
neuropathic and incident component of pain can be sec-
ondary to the tumor itself while the psychological discom-
fort and addictive behaviour can be considered personality
traits. Therefore, the analysis of both the neuropathic (N)
and the incident (I) component of pain was done over the
total number of different types of BTcP detected and the
Psychological (P) and addictive (A) traits were analysed
over the total number of patients included. The Cognitive
(C) component was specifically excluded.
This is the usual protocol applied in order to study pain
when a patient is assessed first time at the outpatient clinic.
Data collection
The following information was extracted from the chart re-
view: age, gender, civil status, cognitive status measured
with Pfeiffer test [39, 40], functional performance status
measured with Barthel test [41, 42] and with Palliative
Performance Scale version 2 test (PPSv2) [43, 44]. Variables
related to the tumour were obtained (primary tumour
diagnosis, metastatic disease and locally advanced disease).
We also extracted the information related to BTcP as
following:
– Related Factors: predictable, unpredictable or
idiopathic (volitional, non-volitional or idiopathic).
– Cause of pain: tumour, treatments received or
idiopathic cause.
– Intensity of pain: measured through a VAS scale.
Minimum and maximum intensity were recorded.
The difference between VAS minimum intensity
(VAS min) and VAS maximum intensity (VAS max)
should be ≥ 3 points measured with scale from
0 to 10.
The ECS-CP was applied in order to detect additional
pain features other than incident pain in the same pa-
tient. The neuropathic component of pain was assessed
through the Doleur Neuropathique-4 questionnaire
(DN4) [45, 46] altogether with the clinical examination.
For the psychological distress we followed the Clinical
Practice Guidelines in Oncology (NCCN) and a VAS ≥ 4
in either anxiety or depression was the cut-off point
[47]. Regarding the addictive behaviour only the addic-
tion to alcohol was collected and measured through Cut
down, Annoyed, Guilty and Eye-opener questionnaire
(CAGE) [48]. Two or more “yes” responses indicated the
possibility of alcoholism.
For each pain features detected by the ECS-CP
(NIPAC), one point was given.
Even if the number of BTcP episodes were specifically
registered in the patients files, they were not included in
the data analysis.
Data analysis
The data included all patients attending the outpatient
clinic of the Catalan University Hospital Arnau de Vilanova
of Lleida between 2014 and 2015. The information for the
study was extracted between June and October 2016.
The study was carried out in two separate phases; in the
first phase the data analyzed was related to the total num-
ber of patients with pain included consecutively in the
study and this sample was further studied according to the
number of different types of pain found (1 types vs. > 1 type
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of pain). In the second phase, data analyzed was related to
the total number of different types of BTcP individualized
after having used the ECS-CP in the diagnostic algorithm
and the sample was also further analyzed depending of the
pain intensity. We considered mild and moderate pain if
the VAS < 7 and severe pain included VAS ≥ 7.
Statistical analyses were conducted using SPSS Statistics
20 (IBM Corporation) and Microsoft Excel (Microsoft
Corporation) software [49]. Continuous variables were
summarized as means and standard deviations (SD).
Categorical variables were summarized as percentages
(absolute numbers). Univariate analysis was performed
using the Wilcoxon or Chi square test without correc-
tion for continuity for comparison among groups of
continuous and categorical variables, respectively. Statis-
tical significance was assumed at a 0.05 level (P < 0.05).
Results
The palliative care team visited a total of 1276 patients
for the first time at the University Hospital Arnau de
Vilanova in Lleida, Catalonia (Spain) between January
2014 and December 2015. 704 of them (55.17%)
attended the outpatient clinic. 303 patients had pain,
and 277 were diagnosed of BTcP and included to the
chart review study. Mean age was 68.2 ± 13 years while
men accounted for 67.9% of the sample. Lung cancer
(31%) was the most prevalent cancer diagnosis and
metastatic disease was found in 83% of the sample.
Fig. 1 Flow Chart of BTcP diagnosis process. Flow chart of patients visited first time in the Palliative care outpatient clinic. Prevalence of BTcP.
Patients diagnosed with BTcP and different types of BTcP according to the ECS-CP classification
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A prevalence of 39.34% of BTcP (277/704 patients) was
found. A total of 488 different types of BTcP were de-
tected (mean of 1.75 ± 0.9 types of BTcP per patient). Up
to 5 different types of BTcP were found among the pa-
tients and 50,2% of patients (N = 139) accounted for ≥ 2
types of BTcP (Fig. 1).
Main characteristics of the population studied are
showed in Table 1. Addictive behavior was detected in
29.2% of the sample and the psychological discomfort
was detected in 40.8%. This table also shows the results
according to two groups of patients (1 type vs > 1 type).
The group of patients with > 1 type was younger (66 ± 12,
p = 0.002), had more metastatic disease (90.6%, p = 0.001)
and presented with more psychological discomfort (47.5%,
p = 0.023). Patients with 1 type of BTcP presented ad-
dictive behavior (CAGE) (34.8%, p = 0.043).
In Table 2, the analysis was performed taking into ac-
count the number of different types of BTcP detected
(N = 488). The use of the ECS-CP tool on each type of
BTcP allowed us to detect that, together with the inci-
dent feature of pain, 50% (N = 244) had a neuropathic
component. Non-volitional component of BTcP was
detected in the 63.7% of the sample. The sum of the dif-
ferent pain features detected by the ECS-CP (NIPAC)
when applied on the sample of 488 different types of
BTcP is 2.2 ± 1.
Discussion
This retrospective study was designed to determine several
outcomes related to BTcP in a sample of advanced cancer
patients who attended the outpatient clinic of a University
hospital during a two-year period (2014–2015).
We identified a prevalence of 39.34% of BTcP in the
sample of patients screened for the study. The applica-
tion of Davies algorithm and a close clinical examination
were the cornerstone for defining pain. This result is
consistent with Deandrea et al. [12] who after a biblio-
graphic research, stated a prevalence of BTcP of 39.9%
for cancer patients attended at the outpatient clinic.
Similar outcome data are reported by Margarit et al. [50]
who, after reviewing data from the American Pain
Foundation, show a prevalence of 35% for those can-
cer patients seen on an ambulatory regime.
To our knowledge, this study provides the first data
regarding the fact that a single patient can present with
more than one type of BTcP. Previous studies only ad-
dress this subject as a single patient having different ep-
isodes of the same BTcP. On the current study, we
found that a total of 488 different types of BTcP were
assessed in a sample of 277 patients. Each patient had
an average of 1.75 BTcP. We remark that more than
half of the patients (139/277) were found to report
more than one type of BTcP. Up to 12 patients pre-
sented with 4 or 5 different types of BTcP (4.3%) while
127 patients (45.9%) presented with 2 or 3 different
types of BTcP.
Younger patients and those presenting with metastatic
disease variables were found statistically significant.
The classification ECS-CP provides further insight into
several characteristics of pain like neuropathic, psycho-
logical distress and addictive behavior features. As the
Incident component of pain is already included in the
ECS-CP, all types of pain found in our study had a
BTcP component. The addictive behaviour (A) was
sensibly higher (29.2%) than the found in the literature.
Parsons et al. [51] and Dev et al. [52] found in their
studies a prevalence of addictive behaviour of 17% in
cancer patients attending an outpatient clinic while
Chow et al. [53] found a poor 7% prevalence rate in an
Table 1 Sociodemographic and medical characteristics of the
patients (N = 277) in relation to the number of BTcP
Total
(n = 277)
BTcP pb
BTcP (1 type)
N = 138
BTcP (> 1 type)
N = 139
Age (years)a 68.2 ± 13 70.4 ± 13 66 ± 12 0.002
Gender (men) (%) 67.9 73.2 62.6 0.059
Civil Status (%) 0.854
Married/couple 71.1 69.6 72.7
Single 6.5 5.8 7.2
Separated/divorced 7.6 8 7.2
Widowed 10.8 11.6 10.1
Missing 4 5.1 2.9
Type tumor (%) 0.508
Lung 31 31.2 30.9
Upper digestive 19.9 21 18.7
Lower digestive 19.1 18.8 19.4
Ear-Nose and
Throat
8.7 10 7.2
Genitourinary
male
8.7 6.5 10.8
Genitourinary
female
4 2.2 5.8
Other 8.7 10.1 7.2
Metastatic disease (%) 83 75.4 90.6 0.001
Pfeiffer Testa 0.8 ± 1 0.9 ± 1 0.6 ± 1 0.068
Barthel Testa 87 ± 17 87 ± 18 87 ± 15 0.409
PPSv2 Testa 64 ± 12 64 ± 12 63 ± 11 0.131
Pain features
Addictive 29.2 34.8 23.7 0.043
Psychological 40.8 34.1 47.5 0.023
Number of BTcP
typesa
1.75 ± 0.9
amean ± standard deviation
bComparison between groups with the χ2 test and for continuous variables
with the Mann-Whitney test
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outpatient palliative radiotherapy clinic. Even if all studies
screened the addictive behaviour using the CAGE ques-
tionnaire, differences found can be explained by the fact
that we recorded the CAGE in current or former drinkers.
The sample of 488 different types of pain found was
further divided according to pain intensity. Only neuro-
pathic nature of pain, the summation of the ECS-CP and
the type of cancer showed significant statistical differences.
The ECS-CP has demonstrated its utility in routine
clinical practice. Arthur et al. [54] found that neuro-
pathic pain and psychological distress were associated
with higher pain intensity. Also a higher sum of ECS-CP
features was associated with higher pain intensity. More
recently the same author found that increasing sum of
ECS-CP features was not predictive of pain management
complexity. Our study shows that a higher sum of
ECS-CP features was found among the group of types of
BTcP with a VAS intensity ≥ 7.
However the study has limitations; first, the study was
carried out in a single institution and data available from
medical records were recorded by a single physician dur-
ing clinical interviews. Second, data from addiction be-
haviour only included alcohol screening through the
CAGE questionnaire.
Our study did not aim to analyse any specific pharma-
cological treatment the patients received. Our study
shows a high prevalence of the neuropathic component
of BTcP, further studies have to address this finding.
The strengths and limitations of this study are the
following:
– This is a retrospective study and prevalence rates are
reported from a single institution and a single
physician recorded the data available from medical
records during clinical interviews.
– This study includes BTcP and incidental pain in
equal terms.
– Data from addiction behaviour only included alcohol
screening through the CAGE questionnaire.
– This study included a large cohort of patients who
had BTcP.
– This study supports the hypothesis that a single
patient can present more than one type of BTcP.
– This study supports the use of screening tools to
better categorize diagnose of Cancer pain.
Conclusions
Our study provides data regarding prevalence of BTcP in
a palliative care outpatient clinic in a single Teaching
Hospital and the result of 39.94% is similar to those
found in the literature.
This retrospective chart review allows determining the
number of different types of BTcP diagnosed in each pa-
tient, regardless the number of episodes of BTcP. This is
possible with the routine use of the ECS-CP in tandem
with the Algorithm of Davies when exploring BTcP in
cancer patients.
This study explores the different pain features associated
to the diagnosis of BTcP. Clinicians have to take into ac-
count several pain features such as the neuropathic nature
of pain, psychological distress and addictive behaviour, as
the optimal therapeutic approach can change.
The existence of more than one type of BTcP in each
patient adds more complexity to the pain assessment.
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Table 2 Characteristics of episodes of incidental pain (n = 488)
according to intensity (maximum VAS ≥ 7)
SAMPLE
(n = 488)
VAS MAX < 7
(n = 305)
VAS MAX ≥ 7
(n = 183)
pb
Due to Tumour 93,0 91,8 95,1 0,168
Due to treatment 8,0 8,5 7,1 0,575
Volitional 36,3 36,7 35,5 0,789
Non volitional 63,7 64,1 35,9 0,618
Neuropathic condition 50,0 45,4 63,0 0,001
∑NIPAC 2,2 ± 1 2,2 ± 1 2,3 ± 1 0,044
Type tumor 0,007
Lung 31,6 35,4 25,1
Upper digestive 18,0 18,7 16,9
Lower digestive 20,1 20,3 19,7
ENT 7,6 6,9 8,7
Genitourinary male 8,4 8,9 7,7
Genitourinary female 5,1 4,3 6,7
Other 9,2 5,6 15,3
Values as percentage
amean ± standard deviation
bComparison between groups with the de χ2 test and for continuous variables
with the Mann-Whitney test
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